FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Osimertinib for the treatment of locally advanced, unresectable Stage III non-small cell lung cancer following chemoradiation therapy. The recommended dose is 80mg daily until disease progression or unacceptable toxicity.
September 25, 2024 | 7:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Osimertinib has received FDA approval for treating locally advanced, unresectable Stage III non-small cell lung cancer after chemoradiation therapy. This approval could enhance AstraZeneca's oncology portfolio and potentially increase revenue.
The FDA approval of Osimertinib for a new indication expands its market potential, likely boosting AstraZeneca's revenue and strengthening its position in the oncology sector. This is a significant development for the company, hence a positive short-term impact on its stock price is expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100